Gold bars to be exempt from tariffs, White House clarifies
In a series of recent transactions, Chan Heng Fai Ambrose, a director and significant shareholder of Impact Biomedical Inc. (NASDAQ:IBO), sold a substantial amount of the company’s common stock. The company, currently valued at $9.4 million, has seen its stock price decline significantly to $0.57, with InvestingPro data showing a 75% drop in the past week alone. The transactions, which took place on March 31 and April 1, 2025, involved the sale of 2,526,918 shares amounting to a total value of approximately $2.9 million. The sales were executed at prices ranging from $0.982 to $1.447 per share. According to InvestingPro analysis, the stock currently trades below its Fair Value, while maintaining a weak financial health score of 1.65 out of 5. InvestingPro subscribers have access to 8 additional key insights about IBO’s performance and outlook.
The transactions were carried out by Chan through Alset International Ltd and Alset Inc., entities in which he has a controlling interest. Following these sales, Chan’s indirect ownership in Impact Biomedical stands at 2,041,248 shares, held through various entities including Global Biomedical Pte. Ltd., Alset International Ltd, and Alset Inc. The stock’s current price represents a 91% decline from its 52-week high of $6.17.
In other recent news, Impact BioMedical Inc. has announced the acquisition of Celios®, a company specializing in air purification technology, in an all-equity deal valued at approximately $1.15 million. This strategic move is part of Impact BioMedical’s efforts to expand its health and wellness portfolio and increase immediate revenue. Celios® is known for its advanced air purification systems, which feature patented designs and methods with exclusivity through 2043, offering high-quality and portable air purification solutions. Impact Biomedical’s CEO, Frank D. Heuszel, highlighted that integrating Celios’ technology aligns with the company’s growth strategy.
Despite the acquisition, Impact BioMedical recently addressed unusual market activity, stating that there were no significant business developments or undisclosed reasons to explain the stock price fluctuations. The biotechnology firm emphasized that no material changes in operations have been reported that would typically affect share value. The company continues to focus on developing innovative healthcare solutions and maintaining transparent communication with investors.
In response to the volatility in its stock, Impact BioMedical reminded stakeholders of the forward-looking nature of its communications, which are subject to various risk factors and uncertainties. While no analyst comments have been provided to shed light on the stock’s recent surge, the company remains committed to its mission and strategic objectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.